Drug Profile
TRK 170
Latest Information Update: 26 Jan 2016
Price :
$50
*
At a glance
- Originator Toray
- Class Antiulcers
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease
Most Recent Events
- 01 Apr 2014 Toray completes a phase II trial in Crohn's disease in Belgium, Bulgaria, Czech Republic, France, Hungary, Latvia, Netherlands, Norway, Poland, Romania, Serbia, Sweden and Ukraine (NCT01345799)
- 27 May 2011 Phase-II clinical trials in Crohn's disease in Bulgaria, Czech Republic, Hungary, Latvia, Netherlands, Poland, Romania, Serbia and Ukraine (PO) after 27 May 2011